660 related articles for article (PubMed ID: 29651407)
1. Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.
Suraweera A; O'Byrne KJ; Richard DJ
Front Oncol; 2018; 8():92. PubMed ID: 29651407
[TBL] [Abstract][Full Text] [Related]
2. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
Singh AK; Bishayee A; Pandey AK
Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer.
Khabele D
Front Oncol; 2014; 4():111. PubMed ID: 24904826
[TBL] [Abstract][Full Text] [Related]
4. Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer.
Pramanik SD; Kumar Halder A; Mukherjee U; Kumar D; Dey YN; R M
Front Chem; 2022; 10():948217. PubMed ID: 36034650
[TBL] [Abstract][Full Text] [Related]
5. Targeting Histone Deacetylases in Diseases: Where Are We?
Benedetti R; Conte M; Altucci L
Antioxid Redox Signal; 2015 Jul; 23(1):99-126. PubMed ID: 24382114
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer.
Amnekar RV; Khan SA; Rashid M; Khade B; Thorat R; Gera P; Shrikhande SV; Smoot DT; Ashktorab H; Gupta S
World J Gastroenterol; 2020 Feb; 26(6):598-613. PubMed ID: 32103870
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer.
Martínez-Iglesias O; Ruiz-Llorente L; Sánchez-Martínez R; García L; Zambrano A; Aranda A
Clin Transl Oncol; 2008 Jul; 10(7):395-8. PubMed ID: 18628067
[TBL] [Abstract][Full Text] [Related]
8. Histone Deacetylase Inhibitors (HDACi) Cause the Selective Depletion of Bromodomain Containing Proteins (BCPs).
Mackmull MT; Iskar M; Parca L; Singer S; Bork P; Ori A; Beck M
Mol Cell Proteomics; 2015 May; 14(5):1350-60. PubMed ID: 25755299
[TBL] [Abstract][Full Text] [Related]
9. Developing histone deacetylase inhibitors as anti-cancer therapeutics.
Venugopal B; Evans TR
Curr Med Chem; 2011; 18(11):1658-71. PubMed ID: 21428881
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors.
Slingerland M; Guchelaar HJ; Gelderblom H
Anticancer Drugs; 2014 Feb; 25(2):140-9. PubMed ID: 24185382
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy.
Elmallah MIY; Micheau O
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31248188
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
[TBL] [Abstract][Full Text] [Related]
13. Fatty acids as histone deacetylase inhibitors: Old biochemistry tales in a new life sciences town.
Ediriweera MK
Drug Discov Today; 2023 May; 28(5):103569. PubMed ID: 36990144
[TBL] [Abstract][Full Text] [Related]
14. Histone Deacetylases and their Inhibitors in Cancer Epigenetics.
Hassell KN
Diseases; 2019 Nov; 7(4):. PubMed ID: 31683808
[TBL] [Abstract][Full Text] [Related]
15. Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma.
Phimmachanh M; Han JZR; O'Donnell YEI; Latham SL; Croucher DR
Front Cell Dev Biol; 2020; 8():578770. PubMed ID: 33117806
[TBL] [Abstract][Full Text] [Related]
16. Liver-Targeting Class I Selective Histone Deacetylase Inhibitors Potently Suppress Hepatocellular Tumor Growth as Standalone Agents.
Tapadar S; Fathi S; Wu B; Sun CQ; Raji I; Moore SG; Arnold RS; Gaul DA; Petros JA; Oyelere AK
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33114147
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylases as targets in autoimmune and autoinflammatory diseases.
Hamminger P; Rica R; Ellmeier W
Adv Immunol; 2020; 147():1-59. PubMed ID: 32981634
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.
Lauffer BE; Mintzer R; Fong R; Mukund S; Tam C; Zilberleyb I; Flicke B; Ritscher A; Fedorowicz G; Vallero R; Ortwine DF; Gunzner J; Modrusan Z; Neumann L; Koth CM; Lupardus PJ; Kaminker JS; Heise CE; Steiner P
J Biol Chem; 2013 Sep; 288(37):26926-43. PubMed ID: 23897821
[TBL] [Abstract][Full Text] [Related]
19. Combination Therapies Targeting HDAC and IKK in Solid Tumors.
Vancurova I; Uddin MM; Zou Y; Vancura A
Trends Pharmacol Sci; 2018 Mar; 39(3):295-306. PubMed ID: 29233541
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
